Humabs BioMed AG

Name: Humabs BioMed AG
Telephone: +41 91 825 63 80

Swiss Biotech Association

Member

Humabs BioMed, a subsidiary of Vir Biotechnology is a leading Swiss antibody therapeutics company that discovers and develops superior antibodies directly derived from individuals who have successfully overcome major diseases.

http://www.vir.bio
+41 91 825 63 80
info@humabs.ch
Filippo Riva

Location

Via dei Gaggini 3, 6500 Bellinzona, Switzerland

Get Directions

Facts & figures

Type of organization

Private company
Year of foundation

2004
Number of employees in Switzerland

20-49

Key business

Core competencies

Therapeutics/vaccines (human)

You may also be interested in

GlycoEra AG

GlycoEra leverages its control over natural glycan-mediated pathways to advance novel drugs using its propriety platform, the CustumGlycan Platform. GlycoEra develops first in class therapeutics in inflammatory disease, autoimmune disorder and immuno-oncology indications.
8952 Schlieren

Member

JFG Life Sciences Stiftung der Universität Basel

Our foundation supports the transfer of innovation from medical research to industry, in particular through young entrepreneurship in Switzerland. We invest in companies in Switzerland or abroad that are active in the field of life sciences. We value strong founding teams and high-quality science.
4051 Basel

Member

Swizzard Pharma AG

Headquartered in Zug, Switzerland, Swizzard Pharma AG's mission is to support pharma/biotech companies in setting up a smart & lean Swiss infrastructure. We build on long-term partnership and offer a quality approach to maximize the value of your medical breakthroughs in Switzerland.
6300 Zug

Member